$AJANTPHARM

Fundamental Analysis: $AJANTPHARM is a specialty pharmaceutical company with a strong presence in branded generics across domestic and international markets. In the latest quarter, the company's revenue grew by 21.47% while net profit increased by 18%. FII holdings rose by 0.29%, reflecting steady institutional interest. The stock trades at a P/E of 35.7x, slightly above the industry average of 31.57x, supported by its consistent earnings growth and strong return ratios. Technical Analysis: The stock has witnessed a sharp recovery from the ₹2,850 zone and is attempting to break out above the ₹3,050 resistance area. Price is trading above its short-term moving averages and near the 50-day EMA, indicating improving momentum. RSI around 51 suggests neutral-to-positive strength. Overall View: With healthy earnings growth, rising institutional participation, and a strengthening technical setup, the stock appears well-positioned for further upside in the near term, supported by an 8.2 Finkhoz Rating.